{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T21:08:44Z","timestamp":1768165724122,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Progress has been made in COVID-19 vaccine development, with encouraging safety and efficacy data.\u00a0The purpose of this study was to investigate the immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Patients with AIIRD (n\u2009=\u2009101) were included in this study.\u00a0All patients received 2 doses of inactivated COVID-19 vaccine. Serum anti-S1\/RBD protein IgG was detected 2\u201316\u00a0weeks after the second vaccination.\u00a0Seropositivity was defined as IgG\u2009\u2265\u20091.00 bound antibody unit S\/CO. Immunogenicity of inactivated COVID-19 vaccine was assessed by seropositivity rate and the levels of serum IgG antibody against anti-S1\/RBD protein, compared with the general population (n\u2009=\u200946). There was no difference by statistical significance in the seropositivity rate between patients with AIIRD (82.2%) and SLE (86.1%) and the control group (93.5%), <jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05. The level of anti-S1\/RBD protein IgG antibodies in patients with AIIRD (median [IQR], 8.8 [2.2\u201317.3]) and SLE (median [IQR], 9.6 [2.4\u201320.4]) was comparable to that in the control group (median [IQR], 7.2 [3.1\u201314.2]), <jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05. Patients treated with glucocorticoids(GCs) (median dose, [IQR]: 2.5\u00a0mg\/day [IQR 2.5\u20135.0]) or hydroxychloroquine(HCQ) or GCs\u2009+\u2009HCQ without other immunomodulatory medications, had an appropriate immunogenic response(88.1%) with high levels of anti-S1\/RBD protein IgG(median [IQR], 12.1 [6.5\u201320.4]). Neither of patients treated with rituximab had positive serum antibodies, which was statistically significant, compared with the control group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). Compared with the control group, methotrexate(MTX) and iguratimod(IGU) was significantly reduced the level of anti-S1\/RBD protein IgG antibodies. Inactivated COVID-19 vaccine had appropriate immunogenicity in patients with AIIRD. Immunogenicity of inactivated COVID-19 vaccine was severely impaired by rituximab, and also suppressed by MTX and IGU,\u00a0while low doses of GC and HCQ had negligible effect.<\/jats:p>","DOI":"10.1038\/s41598-022-22839-0","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T12:04:11Z","timestamp":1666785851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases"],"prefix":"10.1038","volume":"12","author":[{"given":"Yi-Qing","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-Ping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"22839_CR1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1001\/jama.2020.15543","volume":"10","author":"S Xia","year":"2020","unstructured":"Xia, S. et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. JAMA 10, 951\u2013960 (2020).","journal-title":"JAMA"},{"key":"22839_CR2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","volume":"398","author":"MD Tanriover","year":"2021","unstructured":"Tanriover, M. D. et al. Articles efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 398, 213\u2013222 (2021).","journal-title":"Lancet"},{"issue":"1","key":"22839_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"N Al Kaabi","year":"2021","unstructured":"Al Kaabi, N. et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults:\u00a0A randomized clinical trial. JAMA 326(1), 35\u201345 (2021).","journal-title":"JAMA"},{"key":"22839_CR4","unstructured":"Force, D. COVID-19 vaccine clinical guidance summary for patients with rheumatic and musculoskeletal diseases."},{"issue":"3","key":"22839_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/annrheumdis-2021-221736","volume":"81","author":"Y Fan","year":"2022","unstructured":"Fan, Y. et al. Safety and disease flare of autoimmune inflammatory rheumatic diseases: A large real-world survey on inactivated COVID-19 vaccines. Ann. Rheum. Dis. 81(3), 443\u2013445. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221736 (2022) (epub 2021 Nov 25).","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"22839_CR6","doi-asserted-by":"publisher","first-page":"e778","DOI":"10.1016\/S2665-9913(21)00222-8","volume":"3","author":"L Boekel","year":"2021","unstructured":"Boekel, L. et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: A substudy of data from two prospective cohort studies. Lancet Rheumatol. 3(11), e778\u2013e788. https:\/\/doi.org\/10.1016\/S2665-9913(21)00222-8 (2021) (epub 2021 Aug 6).","journal-title":"Lancet Rheumatol."},{"key":"22839_CR7","first-page":"1","volume":"10","author":"V Furer","year":"2021","unstructured":"Furer, V. et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study. Ann. Rheum. Dis. 10, 1\u20139 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"22839_CR8","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","volume":"27","author":"AC Medeiros-Ribeiro","year":"2021","unstructured":"Medeiros-Ribeiro, A. C. et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: A phase 4 trial. Nat. Med. 27, 1744\u20131751 (2021).","journal-title":"Nat. Med."},{"key":"22839_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13075-015-0663-9","volume":"17","author":"L Fischer","year":"2015","unstructured":"Fischer, L. et al. Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases\u2013A longitudinal study. Arthritis Res. Ther. 17, 151 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"22839_CR10","first-page":"e15013","volume":"4","author":"K Pelka","year":"2021","unstructured":"Pelka, K. et al. Hydroxychloroquine does not impair antibody response to 13-valent pneumococcal conjugate vaccine in patients with cutaneous lupus erythematosus\u2014A pilot study. Dermatol. Ther. 4, e15013 (2021).","journal-title":"Dermatol. Ther."},{"issue":"7","key":"22839_CR11","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/acr.22246","volume":"66","author":"C Hua","year":"2014","unstructured":"Hua, C. et al. Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis. Arthritis Care Res. (Hoboken) 66(7), 1016\u20131026 (2014).","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"1","key":"22839_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/cei.12390","volume":"178","author":"J Westra","year":"2014","unstructured":"Westra, J. et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin. Exp. Immunol. 178(1), 40\u201347 (2014).","journal-title":"Clin. Exp. Immunol."},{"key":"22839_CR13","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1136\/annrheumdis-2021-220604","volume":"80","author":"R Spiera","year":"2021","unstructured":"Spiera, R., Jinich, S. & Jannat-Khah, D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases. Ann. Rheum. Dis. 80, 1357\u20131359 (2021).","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"22839_CR14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1136\/annrheumdis-2021-220781","volume":"80","author":"D Mrak","year":"2021","unstructured":"Mrak, D. et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann. Rheum. Dis. 80(10), 1345\u20131350 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"22839_CR15","first-page":"e60","volume":"10","author":"JR Curtis","year":"2021","unstructured":"Curtis, J. R. et al. American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: Version 3. Arthritis Rheumatol. 10, e60\u2013e75 (2021).","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"22839_CR16","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181(7), 1489\u20131501 (2020).","journal-title":"Cell"},{"key":"22839_CR17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","volume":"20","author":"M Jeyanathan","year":"2020","unstructured":"Jeyanathan, M. et al. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 20, 615\u2013632 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"22839_CR18","doi-asserted-by":"publisher","first-page":"001035","DOI":"10.1136\/rmdopen-2019-001035","volume":"5","author":"C Rondaan","year":"2019","unstructured":"Rondaan, C. et al. Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: A systematic literature review for the 2019 update of EULAR recommendations. RMD Open 5, 001035 (2019).","journal-title":"RMD Open"},{"issue":"1","key":"22839_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rdc.2016.09.003","volume":"43","author":"MA Friedman","year":"2017","unstructured":"Friedman, M. A. & Winthrop, K. L. Vaccines and disease-modifying antirheumatic drugs: Practical implications for the rheumatologist. Rheum. Dis. Clin. N. Am. 43(1), 1\u201313 (2017).","journal-title":"Rheum. Dis. Clin. N. Am."},{"issue":"12","key":"22839_CR20","first-page":"2555","volume":"29","author":"AS Mahmoud","year":"2002","unstructured":"Mahmoud, A. S. et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J. Rheumatol. 29(12), 2555\u20132557 (2002).","journal-title":"J. Rheumatol."},{"key":"22839_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3899\/jrheum.170710","volume":"6","author":"S Subesinghe","year":"2018","unstructured":"Subesinghe, S. et al. A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis. J. Rheumatol. 6, 733\u2013744 (2018).","journal-title":"J. Rheumatol."},{"issue":"9","key":"22839_CR22","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1007\/s10067-021-05700-z","volume":"40","author":"M Soy","year":"2021","unstructured":"Soy, M. et al. A practical approach for vaccinations including COVID-19 in autoimmune\/autoinflammatory rheumatic diseases: A non-systematic review. Clin. Rheumatol. 40(9), 3533\u20133545 (2021).","journal-title":"Clin. Rheumatol."},{"issue":"11","key":"22839_CR23","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/rheumatology\/keg381","volume":"42","author":"K Tanaka","year":"2003","unstructured":"Tanaka, K. et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford) 42(11), 1365\u20131371 (2003).","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"22839_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10792-020-01490-6","volume":"40","author":"W Jiang","year":"2020","unstructured":"Jiang, W. et al. The efficacy and mechanism for action of iguratimod in primary Sjgren\u2019s syndrome patients. Int. Ophthalmol. 40(11), 1\u20137 (2020).","journal-title":"Int. Ophthalmol."},{"key":"22839_CR25","doi-asserted-by":"publisher","first-page":"102744","DOI":"10.1016\/j.jaut.2021.102744","volume":"125","author":"C Ferri","year":"2021","unstructured":"Ferri, C. et al. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients\u2019 subgroups. J. Autoimmun. 125, 102744. https:\/\/doi.org\/10.1016\/j.jaut.2021.102744 (2021).","journal-title":"J. Autoimmun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22839-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22839-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22839-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T12:12:28Z","timestamp":1666786348000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-22839-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["22839"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-22839-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"28 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17955"}}